首页|亳丹皮提取液抑制TGF-β1信号通路治疗哮喘小鼠的机制研究

亳丹皮提取液抑制TGF-β1信号通路治疗哮喘小鼠的机制研究

扫码查看
目的 探讨亳丹皮提取液在哮喘小鼠模型中通过调控转化生长因子-β1(TGF-β1)信号通路蛋白表达来减轻气道炎症和气道重塑的作用。方法 采用屋尘螨(HDM)提取液诱导的BALB/c哮喘小鼠模型,分为正常组、模型组、亳丹皮处理组和地塞米松处理组,检测气道高反应性、血清IgE水平、肺组织病理变化、肺泡灌洗液(BALF)炎症因子及TGF-β、SMAD2、α-SMA蛋白表达水平。结果 亳丹皮提取液在哮喘小鼠模型中显示出减少气道高反应性、降低血清IgE水平的潜力;此外,该提取液还可能减少肺组织的纤维化和炎症,并可能通过抑制BALF中的炎症因子及肺组织中TGF-β1信号通路关键蛋白TGF-β、SMAD2和α-SMA的表达来发挥作用。结论 亳丹皮提取液具有治疗哮喘的前景,其作用机制可能与抑制TGF-β1信号通路有关,但该机制仍需进一步研究验证。
Mechanism of Bodanpi Extract in Inhibiting TGF-β1 Signaling Pathway for the Treatment of Asthmatic Mice
Objective To investigate the effect of Bodanpi extract on airway inflammation and remodeling in an asthma mouse model through the regulation of transforming growth factor-β1(TGF-β1)signaling pathway protein expression.Methods An asthma model was established in BALB/c mice using house dust mite(HDM)extract.The mice were divided into normal,model,Bodanpi extract-treated,and dexamethasone-treated groups.Evaluations included measurements of airway hyperresponsiveness(AHR),serum IgE levels,lung tissue pathology,inflammatory cytokines in bronchoalveolar lavage fluid(BALF),and protein expression of TGF-β,small mother against decapentaplegic 2(SMAD2),and α-smooth muscle actin(α-SMA)in lung tissue.Results Bodanpi extract demonstrated potential in reducing AHR and serum IgE levels in the asthma model.Additionally,the extract might alleviate lung tissue fibrosis and inflammation,possibly through the inhibition of inflammatory cytokines in BALF and key proteins(TGF-β,SMAD2,and α-SMA)in the TGF-β1 signaling pathway in lung tissue.Conclusion Bodanpi extract shows promise as a potential treatment for asthma,with its mechanism likely related to the inhibition of the TGF-β1 signaling pathway;however,further research is needed to validate this mechanism.

AsthmaBodanpi extractLung tissueTransforming growth factor-β1 signaling pathwayInflammation

李登峰、陈名武、方涛、程舒鹏

展开 >

中国科学技术大学附属第一医院·安徽省立医院儿科(合肥 230001)

哮喘 亳丹皮提取液 肺组织 TGF-β1信号通路 炎症

2025

成都医学院学报
成都医学院

成都医学院学报

影响因子:0.933
ISSN:1674-2257
年,卷(期):2025.20(1)